Benign Prostatic Hyperplasia: Current Clinical Practice
Authors:
- Bob DjavanBDBob Djavan
- Elisabeth EckersbergerEEElisabeth Eckersberger
- Julia FinkelsteinJFJulia Finkelstein
- Geovanni EspinosaGEGeovanni Espinosa
- Helen SadriHSHelen Sadri
- Roland BrandnerRBRoland Brandner
- Ojas ShahOSOjas Shah
- Herbert LeporHLHerbert Lepor
- 1 September 2010
- journal article
- review article
- Published by Elsevier in Primary Care: Clinics in Office Practice
- Vol. 37 (3) , 583-597
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- α1‐Adrenoceptor subtypes and lower urinary tract symptomsInternational Journal of Urology, 2008
- Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase InhibitorCurrent Topics in Medicinal Chemistry, 2006
- For the motionEuropean Urology, 2006
- Natural history and clinical predictors of clinical progression in benign prostatic hyperplasiaCurrent Opinion in Urology, 2005
- State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaUrology, 2004
- Androgens and male physiology the syndrome of 5α-reductase-2 deficiencyMolecular and Cellular Endocrinology, 2002
- Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology, 2002
- A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionEuropean Urology, 1999
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasiaUrology, 1996